Skip to search formSkip to main contentSkip to account menu

AG 337

Known as: AG-337, AG337 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Quinazolinesnolatrexednolatrexed dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors
PurposeWe recently showed an increase in tumour uptake of 2-[11C]thymidine in patients with gastrointestinal malignancies after… 
Highly Cited
2003
Highly Cited
2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
BACKGROUND Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can… 
Highly Cited
2003
Highly Cited
2003
Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
1998
1998
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Leukemic cells of 27 children [14 patients with initial acute lymphoblastic leukemia (iALL), 8 patients with relapsed ALL (rALL… 
1998
1998
Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model.
The purpose of this study was to determine the intestinal absorption characteristics of AG337, a mechanism-based inhibitor of… 
1997
1997
Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors
Purpose: To establish the maximum tolerated dose (MTD), dose-limiting and other major toxicities and the major pharmacokinetic… 
Review
1997
Review
1997
Antifolates in clinical development.
Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer… 
1996
1996
Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors.
1995
1995
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride…
3,4-Dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)quinazobone dihydrochboride (AG337) is a nonclassical inhibitor of… 
Review
1994
Review
1994
The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.
Thymidylate synthase (TS) is regarded as a good target for the development of quinazoline (folate-based) anticancer agents. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)